BRPI0908635A8 - composto, composição farmacêutica e método de tratamento de câncer - Google Patents

composto, composição farmacêutica e método de tratamento de câncer

Info

Publication number
BRPI0908635A8
BRPI0908635A8 BRPI0908635A BRPI0908635A BRPI0908635A8 BR PI0908635 A8 BRPI0908635 A8 BR PI0908635A8 BR PI0908635 A BRPI0908635 A BR PI0908635A BR PI0908635 A BRPI0908635 A BR PI0908635A BR PI0908635 A8 BRPI0908635 A8 BR PI0908635A8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
cancer treatment
treatment method
cancer
Prior art date
Application number
BRPI0908635A
Other languages
English (en)
Inventor
Yang Haibin
Su Wei-Guo
Zhang Weihan
Xiaoqiang Yan
Ren Yongxin
Cui Yumin
Original Assignee
Hutchison Medipharma Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Entpr Ltd filed Critical Hutchison Medipharma Entpr Ltd
Publication of BRPI0908635A2 publication Critical patent/BRPI0908635A2/pt
Publication of BRPI0908635A8 publication Critical patent/BRPI0908635A8/pt
Publication of BRPI0908635B1 publication Critical patent/BRPI0908635B1/pt
Publication of BRPI0908635B8 publication Critical patent/BRPI0908635B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

composto, composição farmacêutica e método de tratamento de câncer trata-se de compostos de quinazolina apresentados no relatório descritivo. também é apresentado um método de tratamento de câncer com um desses compostos.
BRPI0908635A 2008-06-30 2009-06-30 composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica BRPI0908635B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/164,610 2008-06-30
US12/164,610 US8426430B2 (en) 2008-06-30 2008-06-30 Quinazoline derivatives
PCT/US2009/049182 WO2010002845A2 (en) 2008-06-30 2009-06-30 Quinazoline derivatives

Publications (4)

Publication Number Publication Date
BRPI0908635A2 BRPI0908635A2 (pt) 2015-10-13
BRPI0908635A8 true BRPI0908635A8 (pt) 2018-12-18
BRPI0908635B1 BRPI0908635B1 (pt) 2020-09-01
BRPI0908635B8 BRPI0908635B8 (pt) 2021-05-25

Family

ID=41466556

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908635A BRPI0908635B8 (pt) 2008-06-30 2009-06-30 composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica

Country Status (22)

Country Link
US (2) US8426430B2 (pt)
EP (1) EP2318378B1 (pt)
JP (1) JP5602729B2 (pt)
KR (1) KR101664503B1 (pt)
AU (1) AU2009267136B2 (pt)
BR (1) BRPI0908635B8 (pt)
CA (1) CA2726040C (pt)
CY (1) CY1114842T1 (pt)
DK (1) DK2318378T3 (pt)
ES (1) ES2442946T3 (pt)
HR (1) HRP20140066T8 (pt)
MX (1) MX2010012692A (pt)
MY (1) MY150493A (pt)
NZ (1) NZ589191A (pt)
PH (1) PH12010502934A1 (pt)
PL (1) PL2318378T3 (pt)
PT (1) PT2318378E (pt)
RU (1) RU2505534C2 (pt)
SG (2) SG10201604677RA (pt)
SI (1) SI2318378T1 (pt)
TW (1) TWI407962B (pt)
WO (1) WO2010002845A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9166071B2 (en) 2009-10-27 2015-10-20 Silicor Materials Inc. Polarization resistant solar cell design using an oxygen-rich interface layer
CN102311438A (zh) * 2010-06-30 2012-01-11 和记黄埔医药（上海）有限公司 喹唑啉化合物
CN102906086B (zh) * 2010-06-30 2014-02-12 和记黄埔医药（上海）有限公司 喹唑啉化合物
WO2012000182A1 (en) 2010-06-30 2012-01-05 Hutchison Medipharma Limited Quinazoline compounds
TWI466888B (zh) * 2011-05-25 2015-01-01 Hutchison Medipharma Ltd 喹唑啉化合物
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
CN102659692B (zh) 2012-05-04 2014-04-09 郑州泰基鸿诺药物科技有限公司 双联厄洛替尼及其制备方法
CN102702115A (zh) * 2012-05-24 2012-10-03 盛世泰科生物医药技术(苏州)有限公司 一种4-氯-7-氟-6-硝基喹唑啉的合成方法
CN102775315A (zh) * 2012-07-31 2012-11-14 上海应用技术学院 一种间氨基苯乙炔的制备方法
CN103275018B (zh) * 2013-04-26 2016-03-02 浙江工业大学 4-[3-氯-4-取代苯胺基]-6-取代甲酰氨基喹唑啉类化合物及制备和应用
CN108863951A (zh) * 2017-05-16 2018-11-23 和记黄埔医药（上海）有限公司 化合物的盐及其晶型
WO2020007219A1 (zh) * 2018-07-02 2020-01-09 南京明德新药研发有限公司 一种egfr抑制剂的晶型及其制备方法
CN110903253B (zh) * 2019-12-13 2020-12-25 西安交通大学医学院第一附属医院 一种喹唑啉酮类化合物及其制备方法和应用
CN116917286B (zh) * 2021-03-26 2026-04-28 无锡瓴方生物医药科技有限公司 6-氨基甲酸酯取代的杂芳环衍生物
US20240382475A1 (en) * 2021-08-30 2024-11-21 Zhejiang Hisun Pharmaceutical Co., Ltd. Quinazoline Derivative, Or Preparation Method Therefor And Use Thereof
MX2024010283A (es) * 2022-02-28 2024-08-28 Sironax Ltd Moduladores rip1, preparaciones y usos de los mismos.
CN118834200A (zh) * 2024-06-27 2024-10-25 辽宁大学 含酰胺结构的4-苯胺基喹唑啉类化合物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
JP3370340B2 (ja) * 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
NZ503991A (en) 1997-11-06 2001-11-30 American Cyanamid Co Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
NZ522568A (en) 2000-06-22 2004-12-24 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE60214828T2 (de) * 2001-02-26 2007-09-06 Mcgill University, Montreal Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben
US20040092750A1 (en) * 2001-03-01 2004-05-13 Tomoyuki Hasegawa 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
BR0313059B8 (pt) 2002-07-29 2021-07-27 Rigel Pharmaceuticals composto, e, composição farmacêutica
PA8603801A1 (es) 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
JP4503022B2 (ja) 2003-12-23 2010-07-14 ファイザー・インク 新規キノリン誘導体
WO2006071079A1 (en) 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (ko) * 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US20060281712A1 (en) 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
BRPI0717586A2 (pt) 2006-09-18 2013-10-29 Boehringer Ingelheim Int Método para tratar câncer apresentando mutações do egfr

Also Published As

Publication number Publication date
WO2010002845A2 (en) 2010-01-07
BRPI0908635A2 (pt) 2015-10-13
CA2726040A1 (en) 2010-01-07
KR20110025741A (ko) 2011-03-11
SG10201604677RA (en) 2016-07-28
PT2318378E (pt) 2014-01-03
WO2010002845A3 (en) 2010-04-01
SI2318378T1 (sl) 2014-03-31
ES2442946T3 (es) 2014-02-14
RU2011103207A (ru) 2012-08-10
PL2318378T3 (pl) 2014-05-30
AU2009267136A1 (en) 2010-01-07
CA2726040C (en) 2014-08-12
HRP20140066T1 (hr) 2014-02-28
JP5602729B2 (ja) 2014-10-08
EP2318378B1 (en) 2013-10-23
TWI407962B (zh) 2013-09-11
SG167561A1 (pt) 2011-01-28
KR101664503B1 (ko) 2016-10-12
MY150493A (en) 2014-01-30
EP2318378A2 (en) 2011-05-11
DK2318378T3 (da) 2013-11-18
EP2318378A4 (en) 2012-05-09
US20100009958A1 (en) 2010-01-14
MX2010012692A (es) 2010-12-20
PH12010502934A1 (en) 2010-01-07
JP2011526913A (ja) 2011-10-20
HRP20140066T8 (en) 2014-03-28
US8426430B2 (en) 2013-04-23
US20130217661A1 (en) 2013-08-22
TW201002329A (en) 2010-01-16
AU2009267136B2 (en) 2013-10-10
RU2505534C2 (ru) 2014-01-27
NZ589191A (en) 2013-03-28
BRPI0908635B1 (pt) 2020-09-01
CY1114842T1 (el) 2016-12-14
BRPI0908635B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
EA201171367A1 (ru) Винилиндазолильные соединения
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
ECSP088823A (es) Quinazolinas para la inhibición de pdk1
MX2010009669A (es) Terapia de combinacion con antagonistas de c-met y egfr.
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201001639A1 (ru) Композиции и способы их получения и применения
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
BRPI0908100A2 (pt) produto combinação, uso de um composto, e, método de tratar câncer
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
EA201170832A1 (ru) Пуриновые соединения
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
CL2011000979A1 (es) Compuestos derivados ftalazina 1,4-disustituida; composicion farmaceutica; y su uso en el tratamiento del cancer.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2729 DE 25-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.